MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
Expanded Access to IND – Full Question and Answer in Draft Guidance
A. Expanded Access for Treatment Use Q1. What is expanded access? Q2. Are there safeguards in place for expanded access use of an unapproved drug? B. Expanded Access Submission Q3. What types of regulatory submissions can be used to obtain expanded access to a drug...
Aligning a Global Team, Engaging Colleagues, and the Importance of a Human Connection: A Conversation with Daria Fellrath
In this blog, we sat down with Daria Fellrath, Senior Manager of Global Talent and Culture Management at MMS, to discuss how important it is to align a global team, engage with colleagues, and foster human connections across organizations. Daria’s leadership and...
MMS Named a Great Place to Work in India
BANGALORE, India (1/12/2023) – MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work by the Great Place to Work Institute of India. This award is based on anonymous feedback from a survey sent out to employees and...
Clinical Trial Information System (CTIS) Updates: Cross-Functional Teams are Needed for Success
The Clinical Trials Information System (CTIS) is a single portal for European Union (EU) competent authority and ethics submissions for clinical trial applications (CTAs) across EU member states. The system represents the actualization of the EU Clinical Trials...
A Step-by-Step Approach to Determining Company Confidential Information (CCI) in Redaction Proposal Packages
With all new regulations like Health Canada-PRCI, EMA Policy 0070 and EU-CTR requiring the publication of clinical information, it’s important to understand what is considered company confidential information (CCI) and how to protect the information being shared with...
Exploring the use of Real-World Evidence in Regulatory Decision Making Under PDUFA VII
The PDUFA VII Commitment Letter builds on the programs supporting the use of Real-World Evidence (RWE) in regulatory decision-making begun under PDUFA VI. Specifically, the following initiatives incorporating RWE have been incorporated into PDUFA VII: Pilot Advancing...
Updates to FDA Meetings under PDUFA VII
Sponsors receive FDA feedback and advice on their drug development program via formal FDA meetings. These meetings allow Sponsors to learn the FDA's current thinking on a specific topic and to amend their development program based on FDA's recommendations...
Drug Safety Updates: What’s New Under PDUFA VII?
Patient safety remains at the forefront of the FDA's intentions to continue and enhance existing drug safety programs and develop new ones under PDUFA VII. Commitment to Enhanced Communication on Risk Management Activities During Review Some of the planned...
CMC and Quality Enhancements Under PDUFA VII Explained
FDA establishes numerous enhancements to product quality and chemistry, manufacturing, and controls (CMC) approaches in PDUFA VII to facilitate timely access to safe, effective, and innovative new medicines for patients, including: product quality reviews; CMC...